 |
TSO3 hires four new sales peopleDecember 5, 2005Québec City, December 5, 2005 – TSO3 Inc. (“TSO3”) (TSX: TOS) announces the appointment of four new regional sales managers to support the commercialization efforts for the 125L Ozone Sterilizer in the US territory. Those four representatives have recently completed their training at TSO3 and are already contributing to the sales efforts out in the field.“With the many leads we have been getting over the last few months at trade shows and other promotional events, it was imperative that we hire additional experienced sales people to better support the commercial launch of the 125L Ozone Sterilizer in North America”, said Ann Hewitt, Vice President Sales and Marketing at TSO3. “Those four seasoned sales people have extensive experience working with capital equipment in operating rooms and central sterilization departments in hospitals. They have been successful interfacing with the executive level of hospital administration as well as clinical management, are well-known in the customer marketplace, and are well versed in the capital equipment procurement process. We are very pleased to see them join our sales team”. With the upcoming end of the trial period for several referral sites, TSO3 sees great interest in its product and foresees growing opportunities for the 125L. The addition of these four new resources to the Sales and Marketing Department brings it to 16 members, including Sales Directors and Managers, Clinical Specialists and a Marketing team. About TSO3 TSO3 Inc. is located in Québec City, Québec, Canada, and was founded in 1998. The Company’s mission is to develop and market innovative and comprehensive sterilization solutions. TSO3 has perfected an innovative sterilization process using ozone as the sterilizing agent. The first product based on this technological platform is the 125L Ozone Sterilizer, which is intended for hospital sterilization units. The 125L – named after its 125-litre/4.3-cubic-foot capacity – was designed to sterilize heat and moisture-sensitive surgical and diagnostic devices which are expensive and in high demand from the surgical suite. The ozone sterilization process is a safe, efficacious, fast and cost-effective response to evolving sterilization needs. The 125L Ozone Sterilizer by TSO3 was cleared for commercialization by Health Canada and more recently by the U.S. Food and Drug Administration (FDA). TSO3 expects the first sales of this product in 2005. TSO3 currently has 54 employees, 16 of whom work in the sales and marketing team to support SKYTRON, the company’s exclusive distributor for North America. The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it. - 30 - Source: TSO3 Inc. Information: Caroline Côté Director, Corporate Communications and Investor Relations Phone: (418) 651-0003, ext. 237 Email ccote@tso3.com |
© 2005-2008 TSO3. All Rights Reserved.
